Results 101 to 110 of about 275,929 (307)

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. [PDF]

, 2013
Bispecific antibodies are considered as a promising class of future biotherapeutic molecules. They comprise binding specificities for two different antigens, which may provide additive or synergistic modes of action.
Duerr, Harald, Kettenberger, Hubert, Thomas, Markus, Imhof-Jung, Sabine, Fenn, Sebastian, Christian B Schiller, Harald Duerr, Julia J Griese, Griese, Julia J., Sebastian Fenn, Schiller, Christian B., Regula, Joerg Thomas, Sebastian Fenn, Schaefer, Wolfgang, Christian Klein, Klein, Christian, Christian Gassner, Hubert Kettenberger, Markus Thomas, Gassner, Christian, Julia J. Griese, Hopfner, Karl Peter, Wolfgang Schaefer, Christian B. Schiller, Karl-Peter Hopfner, Moelleken, Joerg, Hopfner, Karl-Peter, Joerg Moelleken, Joerg Thomas Regula, Sabine Imhof-Jung   +29 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Author Correction: A Rift Valley fever mRNA vaccine elicits strong immune responses in mice and rhesus macaques

npj Vaccines, 2023
Ting Bian, Meng Hao, Xiaofan Zhao, Chuanyi Zhao, Gang Luo, Zhendong Zhang, Guangcheng Fu, Lu Yang, Yi Chen, Yudong Wang, Changming Yu, Yilong Yang, Jianmin Li, Wei Chen   +13 more
doaj   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Rapid affinity optimization of an anti-TREM2 clinical lead antibody by cross-lineage immune repertoire mining

Nature Communications
We describe a process for rapid antibody affinity optimization by repertoire mining to identify clones across B cell clonal lineages based on convergent immune responses where antigen-specific clones with the same heavy (VH) and light chain germline ...
Yi-Chun Hsiao, Heidi Ackerly Wallweber, Robert G. Alberstein, Zhonghua Lin, Changchun Du, Ainhoa Etxeberria, Theint Aung, Yonglei Shang, Dhaya Seshasayee, Franziska Seeger, Andrew M. Watkins, David V. Hansen, Christopher J. Bohlen, Peter L. Hsu, Isidro Hötzel   +14 more
doaj   +1 more source

Development of monoclonal antibodies against P. gingivalis Mfa1 and their protective capacity in an experimental periodontitis model

mSphere
Porphyromonas gingivalis (P. gingivalis), a gram-negative, black-pigmented anaerobe, is a major etiological agent and a leading cause of periodontitis. Fimbriae protein Mfa1 is a key virulence factor of P. gingivalis and plays a crucial role in bacterial
Mingya Cao, Siyu Wang, Shengke Zhou, Min Yan, Yu Zou, Yuan Cui, Xinyu Lou, Yichang Gao, Ying Chen, Zijing Han, Yi Qian, Jingying Chen, Xia Li   +12 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Antibody engineering on the surface of CHO cells

, 2017
From discovery to market, antibody therapeutics are developed using several expression platforms. Antibodies are often discovered from isolated mouse or human B-cells, engineered for affinity and specificity on the surface of phage, bacteria, or yeast ...
Maynard, Jennifer, Nguyen, Annalee W.
core  

Module based antibody engineering: a novel synthetic REDantibody

, 2011
We describe the facile generation of a stable recombinant antibody with intrinsic red fluorescent properties for qualitative and potentially quantitative immunofluorescence analysis.
Anani, B., Kang, A.S., Durvasula, Ravi V., Kang, Angray S., Anatoliy Markiv, Anani, Bernard, Bernard Anani, Ravi V. Durvasula, Markiv, A., Durvasula, R.V., Angray S. Kang, Markiv, Anatoliy   +11 more
core   +1 more source